The ongoing uncertainty over the Covid-19 pandemic has tested the resilience of India’s healthcare system. More needs to be done, a survey conducted by Grant Thornton Bharat showed.


The industry expects that innovation and research & development (R&D) will be the key investment drivers. Restoration of a higher percentage of deduction under Section 35(2AB) of the Income-tax Act, 1961 will encourage R&D and innovation.

The survey showed that 81 percent of respondents expect the inclusion of pharmaceutical products in the list of eligible products for the Remission of Duties and Taxes on Export Products (RoDTEP) scheme for encouraging the growth of the sector in India.